MedPath

Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis

Phase 2
Terminated
Conditions
Leptospirosis
Interventions
Registration Number
NCT00592566
Lead Sponsor
Mahidol University
Brief Summary

Background: Pulmonary involvement in leptospirosis has been reported to be on the increase and is emerging as the main cause of death due to leptospirosis in many countries, including Thailand.

Methods: A prospective randomized controlled trial of desmopressin or high dose dexamethasone as adjunctive therapy in patients with suspected pulmonary hemorrhage associated with leptospirosis was conducted between July 2003 and October 2006 at 5 hospitals in Thailand.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
64
Inclusion Criteria
  • adult patients (> 14 years) with suspected severe leptospirosis
  • patients who presented with acute fever (oral temperature more than 38.00 C for <15 days) in the absence of an obvious focus of infection
  • In the opinion of the attending physician might have pulmonary hemorrhage (i.e. history of hemoptysis, and/ or bilateral nodular or air space infiltration).
Read More
Exclusion Criteria
  • pregnant or breastfeeding
  • those with history of bleeding disorder
  • those who had underlying diseases such as chronic liver disease, diabetes mellitus
  • those who received diuretic or glucocorticoid
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2Dexamethasone, desmopressinDexamethasone treatment
3Dexamethasone, desmopressinDesmopressin treatment
Primary Outcome Measures
NameTimeMethod
Survivalduring in hospital admission
Secondary Outcome Measures
NameTimeMethod
Days of mechanical ventilationduring hospital admission

Trial Locations

Locations (1)

Loei Hospital

🇹🇭

Mueng, Loei Province, Thailand

© Copyright 2025. All Rights Reserved by MedPath